ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Intesity Therapeutics Inc

Intesity Therapeutics Inc (INTS)

4.65
-0.13
( -2.72% )
Updated: 11:07:03

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
4.65
Bid
4.76
Ask
4.98
Volume
1,320
4.65 Day's Range 4.76
2.0101 52 Week Range 11.44
Market Cap
Previous Close
4.78
Open
4.76
Last Trade
25
@
4.7758
Last Trade Time
11:06:55
Financial Volume
$ 6,283
VWAP
4.76
Average Volume (3m)
16,258
Shares Outstanding
13,709,377
Dividend Yield
-
PE Ratio
-5.37
Earnings Per Share (EPS)
-0.87
Revenue
-
Net Profit
-11.86M

About Intesity Therapeutics Inc

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to treat solid tumor cancers. It leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive... Intensity Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to treat solid tumor cancers. It leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive immune response that attacks the injected and non-injected tumors. The Company's lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. The Company, through Merck Sharpe & Dohme (Merck), evaluates INT230-6 with pembrolizumab. In addition, it also evaluates the combination INT230-6 with Bristol-Myers Squibb's anti-CTLA-4 antibody, ipilimumab. It also has an agreement with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer (the INVINCIBLE study) (NCT04781725). Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Intesity Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker INTS. The last closing price for Intesity Therapeutics was $4.78. Over the last year, Intesity Therapeutics shares have traded in a share price range of $ 2.0101 to $ 11.44.

Intesity Therapeutics currently has 13,709,377 shares outstanding. The market capitalization of Intesity Therapeutics is $63.75 million. Intesity Therapeutics has a price to earnings ratio (PE ratio) of -5.37.

INTS Latest News

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors PR Newswire SHELTON, Conn., May 15, 2024 SHELTON, Conn., May 15, 2024 /PRNewswire/ -- Intensity...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.33-6.62650602414.9854.6576544.82551082CS
4-0.58-11.08986615685.235.2754.63145814.93824865CS
12-0.86-15.60798548095.515.693.55162584.64534949CS
26-5.35-53.510102.6701566475.46184297CS
52-1.3-21.84873949585.9511.442.01011885256.64664406CS
156-1.3-21.84873949585.9511.442.01011885256.64664406CS
260-1.3-21.84873949585.9511.442.01011885256.64664406CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.04
(270.59%)
41.79M
SVMHSRIVARU Holding Ltd
$ 0.310699
(103.74%)
207.52M
CNSPCNS Pharmaceuticals Inc
$ 6.4619
(78.51%)
5.22M
TOIIWOncology Institute Inc
$ 0.0315
(73.08%)
58.74k
KITTNauticus Robotics Inc
$ 0.2345
(46.11%)
81.56M
NXLNexalin Technologies Inc
$ 0.9079
(-34.22%)
2.96M
INABIN8bio Inc
$ 1.11
(-33.93%)
2.73M
GANXGain Therapeutics Inc
$ 1.2707
(-32.77%)
1.94M
KYTXKyverna Therapeutics Inc
$ 10.20
(-29.36%)
2.23M
QXOQXO Inc
$ 155.00
(-24.54%)
100.78k
SVMHSRIVARU Holding Ltd
$ 0.310699
(103.74%)
207.52M
NVDANVIDIA Corporation
$ 130.68
(0.83%)
138.54M
KITTNauticus Robotics Inc
$ 0.2345
(46.11%)
81.56M
LGVNLongeveron Inc
$ 3.6552
(35.88%)
73.33M
SQQQProShares UltraPro Short QQQ
$ 8.515
(-0.29%)
50.35M

Your Recent History

Delayed Upgrade Clock